Our novel and unique product offerings reflect our key leadership position within the fields of Clinical Diagnostics, Hemostasis, Thrombosis, Fibrinolysis, Cardiovascular Medicine, Oncology and Drug Discovery.

An example of this leadership is our FDA-cleared DVV® line of diagnostic tests, which detect specific antibodies related to conditions associated with Lupus Anticoagulants. ADI currently manufactures and sells worldwide 1,300,000 DVV® tests annually.  Our DVV® and dPT™ products, coupled with our related ELISA systems, make ADI the leading provider of diagnostic tests for the Anti-Phospholipid Syndrome.

Based upon 17 years of clinical studies of breast cancer patients, our PAI-1/uPA tumor tissue biomarker tests (FEMTELLE®) have become recognized as the first Level-of-Evidence 1 biomarker assay system for breast cancer prognosis.  FEMTELLE® already has been in use in Europe for many years and currently awaits US, FDA licensing.

ADI pioneered the initial worldwide marketing of test systems for the diagnosis of blood clots in the vasculature through tests for the measurement of the blood protein D-dimer.  We annually manufacture and sell -- both directly and via leading diagnostic equipment manufacturers --1,400,000 such tests under the tradename DIMERTEST® and related trademarks.